SARS-CoV-2/Coronavirus 2019 (COVID-19) is responsible for the pandemic, which started in December 2019. In addition to the typical respiratory symptoms, this virus also causes other severe complications, including neurological ones. In diagnostics, serological and polymerase chain reaction tests are useful not only in detecting past infections but can also predict the response to vaccination. It is now believed that an immune mechanism rather than direct viral neuroinvasion is responsible for neurological symptoms. For this reason, it is important to assess the presence of antibodies not only in the serum but also in the cerebrospinal fluid (CSF), especially in the case of neuro-COVID. A particular group of patients are people with multiple sclerosis (MS) whose disease-modifying drugs weaken the immune system and lead to an unpredictable serological response to SARS-CoV-2 infection. Based on available data, the article summarizes the current serological information concerning COVID-19 in CSF in patients with severe neurological complications and in those with MS.
【저자키워드】 COVID-19, antibodies, SARS-CoV-2, multiple sclerosis, serology, neuro-COVID, cerebrospinal fluid, 【초록키워드】 pandemic, multiple sclerosis, SARS-COV-2 infection, Infection, drug, immune system, virus, diagnostics, polymerase chain reaction, serum, Viral, Patient, Neurological symptoms, Neurological complications, cerebrospinal fluid, respiratory, information, serological, predict, immune mechanism, serological response, CSF, neurological, Neurological complication, respiratory symptoms, lead, Chain Reaction, available data, severe complications, article, typical respiratory symptoms, polymerase chain, responsible, addition, cause, concerning, presence of antibody, response to vaccination, 【제목키워드】 review, Complication, literature, status, Multiple, Significance,